{
    "symbol": "MCRB",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-04 13:12:18",
    "content": " I would like to remind you that, we will be making forward-looking statements, including potential approval of SER-109 and its status as a first-in-class therapeutic, the timing of a BLA filing and potential product launch, market for SER-109, our development opportunities and the ultimate safety and efficacy data for our product. This process is already underway and we have several key inflection points along this pathway, including near term SER-109 open label study data, the filing of our complete BLA submission, assignment to the timely PDUFA date given our breakthrough therapy status and continued progress with our pre-launch activities alongside Aimmune. And one thing that we find attractive about the 155 program is that, given the unmet need in this population, success both in either reducing the incidence of bloodstream infections or reducing the incidence of graft versus host disease, combined as well as independently, would be meaningful for these particular patients."
}